Study on the prediction of prognosis of patients with acute liver failure treated with artificial liver by serum NLR and IL-6 expression
Abstract
Objective To observe the relationship between the expression of serum interleukin-6 (IL-6) and neutrophil/lymphocyte ratio (NLR) and the prognosis of patients with acute liver failure (ALF) treated with artificial liver.
Methods 80 patients with ALF from January 2021 to October 2023 were included. All of them received artificial liver system treatment. All of the included subjects completed the effective follow-up for three months. The patients were followed up until April 30, 2023. According to the disease outcomes of patients after the end of follow-up, they were divided into survival group and death group. The serum IL-6 and NLR expressions of the two groups were compared, and the relationship between serum IL-6 and NLR expressions and the prognosis of patients with ALF treated with artificial liver was analyzed.
Results At the end of follow-up of 80 patients with ALF, 50 patients survived, with the survival rate of 62.50%; 30 patients died of illness, with the mortality rate of 37.50%. Comparing the general data between the two groups (P>0.05). The expression levels of serum IL-6 and NLR in the death group were higher (P<0.05). The Logistic regression model was built to obtain the equation: y=-9.007+0.106 (IL-6) +0.995 (NLR), the high expressions of serum IL-6 and NLR might be a risk factor for the increased risk of death in patients with ALF after treatment (P<0.05). The receiver operating characteristic (ROC) curve indicated that the area under curve (AUC) of fasting serum IL-6 and NLR expressions in patients with ALF predicting the prognosis of artificial liver treatment were 0.727 and 0.789. When the AUC of serum IL-6 combined with NLR predicting the prognosis of artificial liver treatment in patients with ALF was 0.889, the predictive values were ideal.
Conclusion The expression of serum IL-6 and NLR is correlated with the prognosis of patients with ALF treated with artificial liver. The high expression of serum IL-6 and NLR may be a risk factor for the increased risk of death in patients with ALF after treatment. Clinical intervention can be given to patients with high expression of serum IL-6 and NLR, so as to correct the abnormal expression of serum IL-6 and NLR, and reduce the mortality risk of patients after artificial liver treatment.
Copyright (c) 2025 Xiaojing Liu, Juan Xu, Fenjing Du, Xin Yang, Jintao Hou, Yan Fan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.